Nutra Pharma Corp.
Bringing Healthcare Solutions to the World
Recent News
Press Kit
Drug Development
R&D Pipeline
Nutra Pharma is developing an innovative pipeline of biopharmaceutical products
Signup to receive news and announcements from Nutra Pharma:
First Name:
Last Name:
Infinite Menus, Copyright 2006, OpenCube Inc. All Rights Reserved.


Nutra Pharma Engages Research Group to Validate Portage BioMed Technology
December 08, 2004

Nutra Pharma Corp., a biotechnology holding company that owns rights to patents and intellectual property related to the development of drugs for HIV and Multiple Sclerosis (MS) today announced that it has engaged Eno Research and Development, Inc. (ERDI) to validate the technology of Portage BioMed.

The contract for services provides for a series of validation steps. The first studies will endeavor to characterize Portage BioMed's novel delivery system for chemotherapeutic agents. If these in-vitro studies are successful, animal trials will commence immediately thereafter.

"At Portage BioMed, we have made tremendous strides in the research and analysis of our drug delivery system," commented James M Spear, Portage BioMed's Chief Executive Officer. "Still, it is absolutely necessary to gain third-party validation of this technology," he continued. "The work that is being conducted by ERDI will allow us to better understand our system and may help lead to licensing of this technology to a partner in the Pharmaceutical industry."

"Our goal in this study is to provide an unbiased analysis of their drug delivery system," remarked James Flowers, ERDI's President and Chief Scientific Officer. "A successful system could result in lower doses of chemotherapy for cancer patients, and therefore possibly minimize the associated side-effects," he added.

"We have been extremely pleased with the working relationship that we have fostered with ERDI," said Rik J. Deitsch, Nutra Pharma's Chief Executive Officer. "The scientific staff of ERDI has the expertise necessary to provide the information that we need to move forward with our acquisition of Portage BioMed," he concluded.

SEC Disclaimer

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). Engaging Eno Research and Development to validate Portage BioMed's technology should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

Quick Nav
Nyloxin // Chronic Pain Relief
Read about Jeff Gottfurcht, the first rheumatoid arthritis sufferer to conquer Everest, in Musculoskeletal Health a special section of the Washington Post.


Recent News
August 03, 2017
New Edition of Textbook on Treating Canine Arthritis Includes Nutra Pharma Pain Remedy

June 21, 2017
Nutra Pharma Announcing Launch of Luxury Feet

June 07, 2017
Nutra Pharma Featured on Univision's Spanish-Language News Show: Primer Impacto

Click here to view a Letter to Shareholders from the Company's CEO, Rik J Deitsch.
Facebook   Twitter
Privacy Policy Code of Ethics